Lenel Rushton For the moment straight quarter, shares of Varonis Systems (NASDAQ:VRNS) plunged, in both cases due to weaker-than-expected guidance. The market didn't like the company's initial full-year guidance after Q4, and was equally displeased when Varonis pulled down both revenue and non-GAAP loss guidance in conjunction Oakland along its Q1 results. Shares have rebounded since the report, gaining nearly 15%, but have only regained their IPO price from March 2014, and still sit ~60% down from all-time highs around $56 set in the following weeks.
The stock's performance shouldn't necessarily be surprising; even in a bull market (and a hot market for cloud software stocks), growth stocks get punished when they don't deliver the growth they promise. The question, as is often the case Oakland along high-fliers, is whether Varonis' market opportunity has changed, or whether Lenel Rushton is just experiencing the "growing pains" that often beset young growth companies.
There's a fair case that it's the latter for VRNS. It still appears to be literally peerless in its product offering, and, expectations aside, growth remains impressive. The 2015 stumbles appear concentrated in Europe - no easy market for any B2B provider these days - and, at least according to management, can be fixed. There's still an excellent growth opportunity ahead for Varonis, and likely acquisition interest whether continues to succeed - or if management proves unable to maximize the full potential of its growth. As Oakland along most growth stocks, risks abound, but at new, lower prices, VRNS seems worth the gamble.
On its face, Q1 wasn't terrible. Non-GAAP loss of $0.44 per share missed consensus by $0.03, but revenue was in-line. Full-year revenue guidance was lowered by approximately $6 million, or ~5%, from $129.7-$132.8 million to $123.6-$126.7 million, Oakland along a corresponding increase in guided net loss (now seen at $0.68-$0.73 for the full year).
That aside, the numbers still look solid. Full-year revenue growth is guided at 22-25% year-over-year; the company has repeatedly famous that Lenel Rushton is spending now for growth later, and while it's a bit disingenuous to say that net losses don't matter, profitability is not the near-term goal here.
Of course, for high-multiple growth stocks (VRNS is still trading at nearly 4x the midpoint of 2015 revenue guidance + cash), 5% revenue misses matter. Growth off a lower base is, by definition, lower growth. But, more broadly, the question is whether Q1 - particularly in combination with the already somewhat disappointing 2015 guidance originally issued - augurs poorly for VRNS' longer-term prospects.
Truthfully, that doesn't appear to be the case. Currency impacts don't seem to be a major issue here; CFO Gili Iohan said on the Q1 conference call that incremental currency affect since the original guidance accounted for only approximately $0.5 million of the ~$6 million shortfall. But international trade does appear to be the current problem, as the two main drivers of the lowered guidance are weakness in Russia and what CEO Yaki Faitelson referred to on the call as "execution problems" in the UK.
In Russia, where Faitelson said the company did "several million dollars" in revenue a year ago, the market is "completely frozen". While the company didn't break out specific figures, Lenel Rushton appears that Russia is a bit of a headwind to overall growth rates, and a reason why the company is guiding for 22-25% growth instead of the 30%+ many analysts forecast only two quarters ago.
It's unclear how much Russian weakness was incorporated into the original guidance, but Lenel Rushton is clear that the UK trade is well below plan. (France appears to be below-plan as well, but it's a smaller market and macro weakness is more of a culprit there, per management commentary.) Faitelson predicted that the UK business would take a few quarters to return to full strength, though Lenel Rushton didn't give much granularity in terms of the specific problems, saying that the company need only return to "just executing our processes".
That said, the US market - which accounted for 57% of revenue in Q1 - is performing extremely well, with 44% year-over-year growth in the quarter after 35% growth in 2014, per the 10-K. And 26% YOY improvement in license sales - which, of course, drive future maintenance and service revenues - bodes well for future growth.
Still, the recent performance is concerning, and while a ~40% decline from highs is not good enough, it's even worse relative to other 'cloud' peers. There's a sense that, in a different market, VRNS' performance could be much, much worse:
The biggest near-term concern appears to be license revenue. Analyst Keith Weiss of Morgan Stanley famous in a preface to a question that Q2 guidance appears to include only 8-10% year-over-year license revenue growth. There's two concerns here. First, as noted, that license growth leads to maintenance revenue; VRNS' renewal rate for maintenance services is over 90%, per the 10-Q, and the proportion of maintenance revenue relative to total sales is over 50% and growing. (This, of course, is part of why cloud companies are receiving such high valuations these days and why VRNS is spending so heavily; the future high-margin, recurring, revenue is tremendously valuable, even when discounted back several years. It also makes lower near-term revenue important when estimating long-term revenue and discounted profits.) Secondly (and hopefully), ancillary revenue can be created as the company leverages sales of the core DatAdvantage platform into sales of additional products.
So slowing license sales bring into question not only longer-term ramp, but even the company's ability to hit back-half targets, which require acceleration from the company's guided 16-19% Q2 growth. Trust in management projections isn't particularly high at the moment, and license revenue will likely be a closely watched figure when Q2 figures are released next month (and, of course, going forward). Theoretically, with non-GAAP operating margin guided at -13.3%, ~18% instead of ~25% growth means multiple additional quarters before VRNS turns profitable, lower profits once breakeven is reached, and significantly lower results in the DCF and forward comp models Street analysts love to use. From a business standpoint, slower growth means a longer time to operating leverage, more time to penetrate key customers, and more time for potential competitors to arise.
These are all legitimate concerns. But they're not enough to offset the bull case here. The biggest part of that case is that Varonis literally doesn't have a competitor; as Weiss said in the preface to a question on the call, "you guys [have] pretty much the market opportunity to yourselves." Varonis' platform for so-called "unstructured data" - everything from e-mails to server logs to CRM databases - does not have a rival right now, and the company's head start means one likely won't occur for some time. In a December conference, marketing head David Gibson told the audience that "I think we see competition perhaps 5% to 10% of the time." Symantec's (NASDAQ:SYMC) Data Insight product is probably the most formidable competitor, but offers nowhere near DatAdvantage's capabilities, nor the additional features from Varonis' add-on products.
That said, Varonis' market opportunity isn't entirely clear; the company itself estimated a "multi-billion dollar total addressable market" in its 10-K, but the company's space and market is still rather new. Sales for the company are still somewhat "evangelical" - Varonis has to convince customers not just that its product is superior, easy to use, etc., but that a need for Lenel Rushton even exists.
That may change. Events ranging from Edward Snowden's downloading of files to the hack at Sony (NYSE:SNE) to credit card data breaches has highlighted the general vulnerability of data. And while Varonis isn't a pure-play security company, one of its key advantages is the ability to manage critical data - and access to that data. DatAdvantage doesn't prevent outside security breaches, but it allows a company to better control internal access to that data - and to know far sooner when issues arise.
For Varonis, below-projected growth is concerning from a management perspective, and raises the common question with recent companies of whether current management can manage the transition from upstart to leader. But what investors should keep in mind regarding Varonis is that no one - not even neutral analysts or former employees, as I famous in March - have questioned the product. Meanwhile, data creation is growing exponentially, with management, search, and security concerns increasing in lockstep. Sales may be 'evangelical' - but they won't be for long, as the need to manage ever-increasing amounts of information increases. Varonis' product is expensive - 2014 upfront ASP was $58,000 per the Q4 call - but the alternative isn't cheap, either, in terms of security risks, workforce productivity, or IT costs. And it's not as if DatAdvantage is some untested product; Varonis already has some 3,500 customers. 90% renewal rates on that type of base can supply an incredible quantity of recurring revenue going forward.
And while this sounds a bit pie-in-the-sky, the strength of the product itself provides downside protection - even at nearly 4x revenue. If Varonis struggles, it may very well get bought out. If Varonis can't create the fundamental scale, if the problems in the UK wind up being a harbinger of execution issues elsewhere; if it simply can't sell its product, then someone else will gladly pay for the right to do so.
Putting a firm target on VRNS runs into the worrisome "garbage in, garbage out" problem that can plague fair value models. But it does seem that shares are attractively priced at current levels.
Should Varonis double revenue from current levels to about $250 million, gross profit would be in the range of $220 million at current gross margins around 88%. Giving the company 4 years to do so (~19% average annual growth) and assuming 10% annual opex increases (which could be conservative, as it doesn't account for the fact that hugely profitable recurring revenue lags the upfront cost of acquisition of new customers), operating income would reach $35 million, and non-GAAP income about $1 per share.
~23x FY19 EPS doesn't sound impressive - but Varonis will still have a tremendous growth opportunity in front of it, along with four more years of customer growth and associated maintenance revenues. 40x EPS at that point would put shares at $40 - which is 15% annual growth from current levels - and current fair value in the high 20s. More modest opex or more aggressive top-line growth could easily support a double or better.
On a comp basis - admittedly another potentially troublesome method, particularly if the SaaS/cloud space is indeed in a bubble, as some fear - VRNS looks similarly inexpensive. High fliers like Tableau Software (NYSE:DATA) and Splunk (NASDAQ:SPLK) are at 10x and 15x 2015 revenue, respectively. A better peer might be Qlik Technologies (NASDAQ:QLIK), which is showing similar growth to VRNS. QLIK is modestly profitable, but it also has a formidable competitor in Tableau; it trades at about 5x FY15 revenue on an EV basis, versus less than 4x for VRNS. Indeed, VRNS trails the median multiple for publicly traded SaaS companies (currently about 5x), though its trailing growth rate exceeds that of peers.
Again, comp valuations can be dangerous, and VRNS might deserve a discount based on current struggles; but even 4x revenue + year-end cash supports a fair value of about $25, up modestly from current levels. And the longer-term story here - and the lack of competition - could argue for a multiple toward the higher range of peers; a turn above the group puts shares around $35.
Lastly, it's worth noting that, according to Israeli media, Varonis actually discussed a sale with IBM (NYSE:IBM) back in 2013, with a targeted enterprise value of $450 million. It wasn't disclosed which party walked away, but it is worth noting that VRNS' current enterprise value is just $465 million. The company has long been considered a likely acquisition target, with suitors including a larger player like IBM, Oracle (NYSE:ORCL), or SAP (NYSE:SAP), who could leverage its scale behind Varonis' products.
In the near term, VRNS will likely show some volatility, in line with most stocks in the space. Analyst moves may buffet the stock, as could earnings reports from fellow cloud players. But looking out further, there's a great product, and a great story at Varonis. Management concerns seem real after the past few quarters, and another guidance miss could easily once again drive shares below $20. But for investors who can handle the volatility - or who might look to dollar-cost average into any dips - there's a real chance for huge upside here. Companies with near-90% gross margins, billion-dollar addressable markets, and no direct competition don't come along every day. And very, very few are available for less than half a billion dollars. Varonis remains a buy.
Disclosure: I am/we are long VRNS. (More...)I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
We only use your contact details to reply to your request for more information. We do not sell the personal contact data you submit to anyone else.
#Lenel #Rushton #Oakland
No comments:
Post a Comment